NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
29 May 2012

Cristina Garmendia returns to Ysios Capital as Partner

Barcelona – 29th May, 2012 – Ysios Capital Partners, a venture capital firm specialized in healthcare and biotechnology, today announces that Dr. Cristina Garmendia returns to the management team after her stage as Minister for Science and Innovation of Spain.
15 May 2012

TiGenix Reports Business & Financial Results for the First Quarter 2012

Leuven (BELGIUM) – May 15, 2012 – TiGenix NV (NYSE Euronext: TIG), a leader in the field of cell therapy, today gave a business update and announced the financial results for the first quarter ending March 31, 2012.
14 May 2012

Endosense reports strong momentum for contact-force sensing in catheter ablation at heart rhythm 2012.

GENEVA - May 14, 2012 – Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has reported another year of significant advancement in the move toward making contact-force sensing a standard of care in catheter ablation procedures.
24 Apr 2012

TiGenix obtains manufacturing license for European production facility

Leuven (BELGIUM) – April 24, 2012 – TiGenix (NYSE Euronext: TIG) announced today that further to the cGMP inspection by the Dutch authorities it has obtained the manufacturing authorization for human medicinal products for its European manufacturing plant in Sittard-Geleen in the Netherlands.
17 Apr 2012

TiGenix rheumatoid arthritis Phase IIa study successfully passes last safety hurdle.

Leuven (BELGIUM), Madrid (SPAIN) – April 17, 2012 – TiGenix (NYSE Euronext: TIG) announced today that upon review of the safety data of the first three patients of the third cohort of the company’s Phase IIa clinical trial in rheumatoid arthritis (Cx611) it has received the go-ahead from the independent Safety Monitoring Board to recruit and dose the remaining patients of this cohort.
14 Apr 2012

TiGenix appoints Dr. Guido Schopen as vice president commercial operations.

Leuven (Belgium) – April 10, 2012 – TiGenix NV (NYSE Euronext: TIG), a leader in the field of cell therapy, today announced the appointment of Dr. Guido Schopen as vice president commercial operations.
15 Mar 2012

TiGenix Reports Full Year 2011 Financial Results.

Leuven (BELGIUM) – March 15, 2012 –TiGenix NV (NYSE Euronext: TIG) today gave a business update and announced financial results for the full year 2011.
13 Mar 2012

AM-Pharma Announces Appointment of Industry Expert Guido Magni as Board Member.

Bunnik, The Netherlands, 16 March 2012. AM‐Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (AP) for treatment of Acute Kidney Injury and inflammatory bowel diseases, has appointed Dr Guido Magni as a member of its Supervisory Board.
16 Feb 2012

TiGenix announces changes in management responsibilities.

Leuven (BELGIUM) – February 16, 2012 – TiGenix (NYSE Euronext: TIG) announced today changes to executive responsibilities within the Company.
01 Feb 2012

TiGenix rheumatoid arthritis Phase IIa study opens third and last cohort.

Leuven (BELGIUM), Madrid (SPAIN) – February 1, 2012 – TiGenix (NYSE Euronext: TIG) announced today that upon review of the safety data of the first three patients of the second cohort of the company’s Phase IIa clinical trial in rheumatoid arthritis (Cx611) it has received the go-ahead from the independent Safety Monitoring Board to recruit and dose the remaining 20 patients of this cohort and to open the third and final cohort.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка